Paid Clinical Trials Billings

Discover 142 paid clinical trials in Billings, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 142

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Billings MT, Cody WY, Sheridan WY, Bozeman MTshow 706 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by BayerStudy to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Recruiting

PHASE3

Sponsor:

Bayer

Location:

Billings MT, Salt Lake City UT, Calgary, Denver COshow 46 more

Code:

NCT04464226

Conditions

Cancer

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Darolutamide (Nubeqa, BAY1841788)

Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

Recruiting

Sponsor:

Vertex Pharmaceuticals Incorporated

Location:

Billings MT, Boise ID, Spokane WA, Sioux Falls SDshow 22 more

Code:

NCT06506773

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 0 - 6

Healthy Volunteers: Not accepted

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryUsing Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Billings MT, Bozeman MT, Great Falls MT, Anaconda MTshow 109 more

Code:

NCT05111574

Conditions

Anal Melanoma

Bladder Melanoma

Cervical Melanoma

Esophageal Melanoma

Gallbladder Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography

MFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaMFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Recruiting

PHASE3

Sponsor:

Alliance for Clinical Trials in Oncology

Location:

Billings MT, Cody WY, Sheridan WY, Bozeman MTshow 465 more

Code:

NCT05677490

Conditions

Advanced Esophageal Adenocarcinoma

Advanced Gastric Adenocarcinoma

Advanced Gastroesophageal Junction Adenocarcinoma

Clinical Stage III Esophageal Adenocarcinoma AJCC V8

Clinical Stage III Gastric Cancer AJCC V8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Fluorouracil

Leucovorin Calcium

Oxaliplatin

Irinotecan

Nivolumab

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentTesting the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Billings MT, Bozeman MT, Great Falls MT, Missoula MTshow 42 more

Code:

NCT06589804

Conditions

Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic Hypopharyngeal Squamous Cell Carcinoma

Metastatic Laryngeal Squamous Cell Carcinoma

Metastatic Oral Cavity Squamous Cell Carcinoma

Metastatic Oropharyngeal Squamous Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Cetuximab

Computed Tomography

Magnetic Resonance Imaging

Pembrolizumab

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Billings MT, Spokane WA, Richland WA, Edmontonshow 40 more

Code:

NCT05221840

Conditions

Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Durvalumab

Oleclumab

Monalizumab

Placebo

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesA Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Billings MT, Salt Lake City UT, Boise ID, Aurora COshow 81 more

Code:

NCT06564844

Conditions

Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Datopotamab Deruxtecan

Rilvegostomig

Carboplatin

Cisplatin

Etoposide

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialChemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Billings MT, Bozeman MT, Great Falls MT, Anaconda MTshow 213 more

Code:

NCT06096844

Conditions

Advanced Lung Non-Small Cell Carcinoma

Stage IIIB Lung Cancer AJCC v8

Stage IIIC Lung Cancer AJCC v8

Stage IV Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 70+

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Computed Tomography

Magnetic Resonance Imaging

Nab-paclitaxel

Paclitaxel

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate CancerTesting the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Billings MT, Great Falls MT, Sioux Falls SD, Willmar MNshow 232 more

Code:

NCT04134260

Conditions

Prostate Adenocarcinoma

Stage I Prostate Cancer AJCC v8

Stage II Prostate Cancer AJCC v8

Stage IIA Prostate Cancer AJCC v8

Stage IIB Prostate Cancer AJCC v8

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Apalutamide

Hormone Therapy

Quality-of-Life Assessment

Questionnaire Administration

Radiation Therapy